Four new safety referrals evaluated as impact of new legislation kicks in
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) held its fifth meeting from 26-29 November 2012.
At the meeting, the PRAC started a review of four medicines that are nationally authorised in EU Member States. The Committee also evaluated evidence for new safety signals from EU reporting systems, assessed updated risk management plans for certain medicines and discussed a number of periodic safety update reports.
Since the PRAC’s first meeting in July 2012, fresh procedures have started under the new pharmacovigilance legislation. The increasing number of reviews for the PRAC, triggered by EU Member States, indicates that the legislation is working effectively and underlines that Member States view the PRAC as the effective mechanism for assessing all aspects of risk management for human medicines.
For an overview of all information available following the meeting of the PRAC, see the table below:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/11/news_detail_001666.jsp&mid=WC0b01ac058004d5c1
The minutes from the fourth PRAC meeting, which took place from 29-31 October 2012, will be published early next week.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.